Peninsula drug company takes big step toward peanut allergy drug approval

Aimmune Therapeutics Inc.'s quest to sell the first biologic drug to treat peanut allergies won a regulatory advisory committee's blessing Friday, moving the company closer to Food and Drug Administration approval. The action by the nine-member panel doesn't guarantee that the FDA will approve the drug, which would be branded as Palforzia, from Brisbane-based Aimmune (NASDAQ: AIMT). Advisory committee recommendations, however, typically hold great sway with the regulator. Palforzia is groundbreaking,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news